Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

References

• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Tamura SI, Kurata T. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn. J. Infect. Dis.53(3), 98–106 (2000).
   PubMed Web of Science ®Google Scholar
• Zurbriggen R, Metcalfe IC, Glück R, Viret J-F, Moser C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev. Vaccines2(2), 295–304 (2003).
   PubMedGoogle Scholar
• Holmes R, Jobling MG, Connell T. Cholera toxin and related enterotoxins of Gram-negative bacteria. In: Bacterial Toxins and Virulence Factors in Disease. Handbook of Natural Toxins. Moss J, Iglewski B, Vaughn M, Tu AT (Eds). Marcel Dekker, Inc., NY, USA 225–255 (1995).
   Google Scholar
• Fraser SA, de Haan L, Hearn AR et al. Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect. Immun.71(3), 1527–1537 (2003).
   PubMed Web of Science ®Google Scholar
• Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine19, 2701–2707 (2001).
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J. Virol.77(9), 5218–5225 (2003).
   PubMed Web of Science ®Google Scholar
• Chandra G, Cogswell JP, Miller LR et al. Cyclic AMP signaling pathways are important in IL-1 β transcriptional regulation. J. Immunol.155(10), 4535–4543 (1995).
   PubMed Web of Science ®Google Scholar
• Platzer C, Fritsch E, Elsner T, Lehmann MH, Volk HD, Prosch S. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur. J. Immunol.29(10), 3098–3104 (1999).
   PubMed Web of Science ®Google Scholar
• Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL, Rapoport TA. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J.22(17), 4346–4355 (2003).
   PubMed Web of Science ®Google Scholar
• Rogers TB, Snyder SH. High affinity binding of tetanus toxin to mammalian brain membranes. J. Biol. Chem.256(5), 2402–2407 (1981).
   PubMed Web of Science ®Google Scholar
• Zoeteweij J-P, Epperson DE, Porter JD et al. GM1-binding deficient exotoxin is a potent non-inflammatory broad-spectrum intradermal immunoadjuvant. J. Immunol.177(2), 1197–1207 (2006).
   PubMed Web of Science ®Google Scholar
• Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines2(2), 285–293 (2003).
   PubMedGoogle Scholar
• Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM. Immunostimulant patch enhances immune responses to influenza vaccine in aged mice. J. Virol.78(14), 7610–7618 (2004).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest.113, 998–1007 (2004).
   PubMed Web of Science ®Google Scholar
• Ghose C, Kalsy A, Shiekh A et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A neutralizing antibodies in mice. Infect. Immun.75, 2826–2832 (2007).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med.6(12), 1403–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Kenney R, Yu J, Guebre-Xabier M et al. Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis.190, 774–782 (2004).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine25(18), 3684–3691 (2007).
   PubMed Web of Science ®Google Scholar
• Yu J, Cassels F, Scharton-Kersten T et al. Transcutaneous immunization using colonization factor and heat labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.Infect. Immun.70(3), 1056–1068 (2002).
   PubMed Web of Science ®Google Scholar
• Milling SW, Yrlid U, Jenkins C, Richards CM, Williams NA, MacPherson G. Regulation of intestinal immunity: effects of the oral adjuvant Escherichia coli heat-labile enterotoxin on migrating dendritic cells. Eur. J. Immunol.37(1), 87–99 (2007).
   PubMed Web of Science ®Google Scholar
• Belyakov IM, Derby MA, Ahlers JD et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl Acad. Sci. USA95(4), 1709–1714 (1998).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. In: Mass Vaccination: Global Aspects –Progress and Obstacles. Plotkin SA (Ed.). Springer Verlag, Berlin-Heidelberg, Germany 247–268 (2006).
   Google Scholar
• Egawa M, Hirao T, Takahashi M. In vivo estimation of stratum corneum thickness from water concentration profiles obtained with Raman spectroscopy. Acta Derm. Venereol.87(1), 4–8 (2007).
   PubMed Web of Science ®Google Scholar
• Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm. Venereol.83(6), 410–413 (2003).
   PubMed Web of Science ®Google Scholar
• Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol.124(6), 869–871 (1988).
   PubMed Web of Science ®Google Scholar
• Huzaira M, Rius F, Rajadhyaksha M, Anderson RR, Gonzalez S. Topographic variations in normal skin, as viewed by in vivo reflectance confocal microscopy. J. Invest. Dermatol.116(6), 846–852 (2001).
   PubMed Web of Science ®Google Scholar
• Lock-Andersen J, Therkildsen P, de Fine Olivarius F et al. Epidermal thickness, skin pigmentation and constitutive photosensitivity. Photodermatol. Photoimmunol. Photomed.13(4), 153–158 (1997).
   PubMed Web of Science ®Google Scholar
• Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature’s adjuvants. Adv. Dermatol.14, 209–258 (1999).
   PubMedGoogle Scholar
• Yu RC, Abrams DC, Alaibac M, Chu AC. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br. J. Dermatol.131(6), 843–848 (1994).
   PubMed Web of Science ®Google Scholar
• van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MB. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol.178(4), 1986–1990 (2007).
   PubMed Web of Science ®Google Scholar
• Udey MC. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol.107(Suppl. 1), 6–8 (1997).
   Google Scholar
• Güereña-Burgueño F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun.70(4), 1874–1880 (2002).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT (Ed.). Methods in Molecular Medicine. Humana Press, Inc., NJ, USA (2000).
   Google Scholar
• Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an ETEC vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun.75(5), 2163–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Frerichs DM, Frech SA, Flyer DC, Yu J, Glenn GM. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine (In Press).
   Google Scholar
• Look JL, Butler B, Al-Khalili M et al. The adjuvant patch: a universal dose sparing approach for pandemic and conventional vaccines. BioPharm International Guide to Vaccine Development & Manufacturing20(Suppl.), 34–45 (2007).
   Google Scholar
• Glück R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis.181(3), 1129–1132 (2000).
   PubMed Web of Science ®Google Scholar
• Sack DA, Sack RB. Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect. Immun.11(2), 334–336 (1975).
   PubMed Web of Science ®Google Scholar
• FDA Draft Guidance for Industry, Stability Testing of Drug Substances and Drug Products. Food and Drug Administration, Rockville, MD, USA (1998).
   Google Scholar
• ICH Guidance for Industry, Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Food and Drug Administration, Rockville, MD, USA. Federal Register, 2339–2340 (2003).
   Google Scholar
• ICH Guidance for Industry, Q1A(R2): Stability Testing of New Drug Substances and Products (Second Revision). Food and Drug Administration, Rockville, MD, USA. Federal Register, 65717–65718 (2003).
   Google Scholar
• Lucas TI, Bishara RH, Seervers RH. A stability program for the distribution of drug products. Pharm. Technol.2, 68–73 (2004).
   Google Scholar
• Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine18(17), 1847–1854 (2000).
   PubMed Web of Science ®Google Scholar
• Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine19(20–22), 2908–2917 (2001).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature391(6670), 851 (1998).
   PubMed Web of Science ®Google Scholar
• Scharton-Kersten T, Yu J, Vassell R, O’Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun.68(9), 5306–5313 (2000).
   PubMed Web of Science ®Google Scholar
• Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun.63(5), 1617–1623 (1995).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol.236, 215–236 (1999).
   PubMed Web of Science ®Google Scholar
• Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology116(4), 804–812 (1999).
   PubMed Web of Science ®Google Scholar
• Snider DP. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol.15(3–4), 317–348 (1995).
   PubMed Web of Science ®Google Scholar
• Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun.68(5), 2775–2782 (2000).
   PubMed Web of Science ®Google Scholar
• Neidleman JA, Ott G, O’Hagan D. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O’Hagan D (Ed.). Humana Press, Totowa, NJ, USA 327–336 (2000).
   Google Scholar
• Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol.158(2), 834–841 (1997).
   PubMed Web of Science ®Google Scholar
• Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl Acad. Sci. USA97(1), 371–376 (2000).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev.47(4), 510–550 (1983).
   PubMedGoogle Scholar
• Dell K, Koesters R, Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int. J. Cancer118(2), 364–372 (2005).
   Web of Science ®Google Scholar
• Itoh T, Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J. Immunother.28(5), 430–437 (2005).
   PubMed Web of Science ®Google Scholar
• Klimuk SK, Najar HM, Semple SC, Aslanian S, Dutz JP. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J. Invest. Dermatol.122(4), 1042–1049 (2004).
   PubMed Web of Science ®Google Scholar
• Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol.174(5), 2476–2480 (2005).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol.80(10), 4962–4970 (2006).
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun.69(6), 3581–3590 (2001).
   PubMed Web of Science ®Google Scholar
• Frech SA, Kenney RT, Spyr CA, Lazar H, Glück R, Glenn GM. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine23(7), 946–950 (2005).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun.67(3), 1100–1106 (1999).
   PubMed Web of Science ®Google Scholar
• Hammond SA, Tsonis C, Sellins K et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv. Drug Deliv. Rev.43, 45–55 (2000).
   PubMed Web of Science ®Google Scholar
• Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine24(35–36), 6110–6119 (2006).
   PubMed Web of Science ®Google Scholar
• Glenn GM. Advanced development of antigen sparing pandemic influenza vaccines. Department of Health and Human Services Contract No. HHSO100200700031C, Washington DC, USA (2007).
   Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers’ diarrhea. J. Travel Med.12(2), 102–107 (2005).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol.161(7), 3211–3214 (1998).
   PubMed Web of Science ®Google Scholar
• Glenn G, Frech S, Villar C et al. Transcutaneous immunization with the heat labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) protects in a Phase II field trial in travelers to Guatemala (GU) and Mexico (MX). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, September 17–20, 2007 (Abstract 3810).
   Google Scholar